HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AKB-4924

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - AKB-4924: 7
  - Piperazines: 26
    - AKB-4924: 7

Experts

1.	Nizet, Victor: 3 articles (01/2018 - 08/2013)
2.	Grover, S P: 1 article (01/2018)
3.	Gupta, Naveen: 1 article (01/2018)
4.	Humphries, J: 1 article (01/2018)
5.	Lyons, O T: 1 article (01/2018)
6.	Mazzone, M: 1 article (01/2018)
7.	Modarai, B: 1 article (01/2018)
8.	Patel, A S: 1 article (01/2018)
9.	Saha, P: 1 article (01/2018)
10.	Serneels, J: 1 article (01/2018)

Related Diseases

1.	Colitis 02/01/2015 - "Using a chemically induced trinitrobenzene sulfonic acid murine model of colitis, we compared the efficacy of oral and intraperitoneal (i.p.) delivery of the PHDi; AKB-4924 in preventing colitis, as measured by endoscopy, histology, barrier integrity, and immune profiling. " 02/01/2015 - "Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis." 01/01/2014 - "Taken together, these results indicate that inhibition of prolyl hydroxylase with AKB-4924 enhances innate immunity and identifies that the epithelium is a central site of inflammatory protection afforded by PHDi in murine colitis. " 01/01/2014 - "Mice with colitis induced by trinitrobenzene sulfonic acid were treated with AKB-4924, a new HIF-1 isoform-predominant PHDi, and clinical, immunological, and biochemical endpoints were assessed. "
2.	Infections 08/10/2013 - "The HIF-boosting drug AKB-4924 has the potential to enhance the immune response even in the complex environment of bacterial skin infections." 04/01/2015 - "AKB-4924 impairs infection in uroepithelial cells and bladders, and could be correlated with enhanced production of nitric oxide and antimicrobial peptides cathelicidin and β-defensin-2. "
3.	Lung Injury 01/01/2018 - "In vivo, AKB-4924 enhanced MSC therapeutic capacity in experimental pneumonia as quantified by a sustainable survival benefit, greater bacterial clearance from the lung, decreased lung injury, and reduced inflammatory indices. "
4.	Weight Loss (Weight Reduction) 01/01/2014 - "Administration of AKB-4924 led to significantly reduced weight loss and disease activity compared with vehicle controls. "
5.	Thrombosis (Thrombus) 01/01/2018 - "Treatment with selective pan PHD inhibitors, AKB-4924 and JNJ-42041935, enhanced thrombus neovascularisation (P < 0.05), but had no significant effect on overall thrombus resolution. " 01/01/2018 - "Thrombus resolution was quantified in mice treated with pan PHD inhibitors AKB-4924 and JNJ-42041935 or inducible all-cell Phd2 knockouts by micro-computed tomography, 3D high frequency ultrasound or endpoint histology. "

Related Drugs and Biologics

1.	Sulfonic Acids
2.	Cytokines
3.	Prolyl Hydroxylases (Prolyl Hydroxylase)
4.	Prolyl-Hydroxylase Inhibitors
5.	Cathelicidins
6.	Protein Isoforms (Isoforms)
7.	Interleukin-10 (Interleukin 10)
8.	Interleukin-6 (Interleukin 6)
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10.	Nitric Oxide (Nitrogen Monoxide)